Viewing Study NCT01289535


Ignite Creation Date: 2025-12-24 @ 10:35 PM
Ignite Modification Date: 2025-12-28 @ 5:07 AM
Study NCT ID: NCT01289535
Status: UNKNOWN
Last Update Posted: 2011-12-30
First Post: 2011-02-02
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years
Sponsor: Hospices Civils de Lyon
Organization:

Study Overview

Official Title: Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years
Status: UNKNOWN
Status Verified Date: 2011-12
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: Expand IDWP21
Brief Summary: This study is the first step in a clinical research program that aims to study the immune response to influenza vaccine in the elderly and then to propose a new method of administering the vaccine.

Influenza can cause severe complications in patients at risk (elderly and subjects vulnerable because of a chronic underlying disease). Over 90% of deaths related to influenza occur in people aged over 65 years.

Vaccination is the most effective way to prevent infection. The World Health Organization recommends annual immunization for people at risk, including all persons aged over 65 years, to reduce the risk of morbidity and mortality related to influenza.

However, the immune response to influenza vaccine appears to be lower in elderly than in young people.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: